Alnylam Shatters Q1 Estimates, Posts First $1 Billion Product Revenue Quarter, Stock Surges
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) delivered a blockbuster first quarter that significantly exceeded analyst expectations, driven by explosive growth in its flagship TTR franchise and marking the first time the company has surpassed $1 billion in quarterly product sales. The market responded enthusiastically, with shares indicating a strong pre-market gain of over 4.5%.
Revenue and Earnings Crush Expectations
The company reported a Non-GAAP net income of $273 million, or $1.99 per diluted share for the first quarter of 2026. This handily beat the analyst consensus estimate of $0.95 per share.
Total revenues came in at $1.167 billion, a 96% increase year-over-year. This also sailed past the analyst estimate of $1.136 billion.
The outperformance was largely driven by a massive surge in product revenues, which totaled $1.036 billion, up 121% compared to the same period last year.
Quarterly Performance vs. Analyst Estimates
- Reported Non-GAAP EPS: $1.99
- Analyst Consensus EPS Estimate: $0.95
- Reported Total Revenue: $1.167 billion
- Analyst Consensus Revenue Estimate: $1.136 billion
The AMVUTTRA Effect Drives Record Numbers
The primary engine of this growth is clearly AMVUTTRA, the company's treatment for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). One year after its U.S. launch for this indication, the drug is scaling rapidly.
Key financial highlights from the quarter include:
- Total TTR Franchise Revenues: Combined net product revenues for AMVUTTRA and ONPATTRO reached $910 million, a 153% increase year-over-year.
- AMVUTTRA alone: Generated $890 million in net product revenue, up 187% from Q1 2025, driven by increased patient demand for ATTR-CM in the U.S.
- Total Rare Revenues: GIVLAARI and OXLUMO contributed a combined $126 million, up 15% year-over-year.
- Royalty Revenue: Reached $49 million, up 85% due to increased sales of Novartis's Leqvio.
- Profitability: The company swung from a GAAP net loss of $18 million in Q1 2025 to a net income of $206 million.
Pipeline and Strategic Developments
Beyond the financial results, Alnylam provided several important updates on its pipeline:
- Nucresiran Expansion: The company announced an expansion of the TRITON-CM Phase 3 study for nucresiran, its next-generation TTR silencer, increasing target enrollment from 1,250 to approximately 1,750 patients. Despite this, the launch timeline for ATTR-CM remains on track for 2030.
- New Obesity Program: Alnylam initiated a Phase 1 clinical trial for ALN-2232, its first adipose-targeted RNAi therapeutic for obesity and weight management, signaling a move into a massive new market.
- Zilebesiran Progress: Presented positive Phase 2 safety data for zilebesiran, its hypertension treatment, at a recent medical conference.
- Regeneron Partnership: Regeneron has submitted an NDA to the FDA for cemdisiran, an RNAi therapeutic for generalized myasthenia gravis.
2026 Outlook Maintained
Alnylam reiterated its full-year 2026 financial guidance. This provides a clear benchmark against analyst projections. The company expects:
- Total Net Product Revenues: $4.9 billion to $5.3 billion.
- Total TTR Net Product Revenues: $4.4 billion to $4.7 billion.
- Total Rare Net Product Revenues: $500 million to $600 million.
- Non-GAAP R&D and SG&A Expenses: $2.7 billion to $2.8 billion.
Note: Analyst estimates had pegged full-year 2026 revenue (this includes collaboration and royalty revenue) at approximately $6.825 billion, with total net product sales estimated at $5.67 billion. The company's guidance of $5.3 billion in product revenue at the high end is below that top-line sales estimate, but the strong Q1 beat suggests the company is off to a very strong start.
Market Reaction
The market has clearly interpreted this report as a strong positive catalyst. The immense revenue beat, combined with achieving profitability and a sustained growth trajectory from AMVUTTRA, has overshadowed the narrower product revenue guidance for the full year.
- Pre-Market Reaction: Indicated a surge of +4.58% .
- Recent Weakness Context: This positive reaction comes after a period of weakness, with the stock down approximately 3% in the last week and 9% over the last month, suggesting the earnings report has successfully reversed a recent downtrend.
Dig Deeper into the Data
For a comprehensive look at Alnylam's historical earnings performance and to track future expectations against analyst projections, visit:
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Financial markets involve risk, and you should conduct your own research or consult with a qualified financial advisor before making any investment decisions.